Genetic Table of Contents

Search:

» Medical Policy

» Medication Policy

» Dental Policy

» Clinical Position Statements

» Practice Guidelines

» Uniform Glossary of Terms

Genetic Testing Section

Policy Name	Date Modified
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening	01/01/2013
Apolipoprotein E for Risk Assessment and Management of Cardiovascular Disease	03/01/2013
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer	06/01/2013
BCBR-ABL 1 Testing for Chronic Myeloid Leukemia	06/01/2013
BRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy	02/01/2013
Chromosomal Microarray Analysis (CMA) for the Genetic Evaluation of Patients with Developmental Delay/Intellectual Disability or Autism Spectrum Disorders	01/01/2013
Cytochrome p450 Genotyping	01/10/2013
DNA-Based Testing for Adolescent Idiopathic Scoliosis	03/01/2013
Epidermal Growth Factor Receptor (EGFR) Mutation Analysis for Patients with Non-Small Cell Lung Cancer (NSCLC)	02/01/2013
Gene Expression Testing to Predict Coronary Artery Disease	03/01/2013
Gene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer	01/01/2013
Genetic Testing for Congenital Long QT Syndrome	03/01/2013
Genetic and Molecular Diagnostic Testing	03/01/2013
Genetic Testing for Hereditary Hemochromatosis	03/01/2013
Genetic Testing for Cutaneous Malignant Melanoma	05/01/2013
Genetic Testing for Familial Alzheimer's Disease	05/01/2013
Genetic Testing for FMR1 mutations (including Fragile X Syndrome	05/01/2013
Genetic Testing for Hereditary Breast and/or Ovarian Cancer	02/01/2013
Genetic Testing for Inherited Thrombophilia	05/01/2013
Genetic Testing for Lynch Syndrome	02/01/2013
JAK2 and MPL Mutation Analysis in Myeloproliferative Neoplasms	05/01/2013
KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy	01/01/2013
KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC)	06/01/2013
KRAS and BRAF Mutation Analysis in Colorectal Cancer	03/01/2013
Microarray-Based Gene Expression Testing for Cancers of Unknown Primary	05/01/2013
Multigene Expression Assay for Predicting Recurrence in Colon Cancer	01/01/2013
Non-BRCA Breast Cancer Risk Assessment (OncoVue®)	05/01/2013
PathFinderTG® Molecular Testing	07/01/2012
Preimplantation Genetic Testing	01/01/2013
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA	04/01/2013


	The Blue Cross and/or Blue Shield Plans comprising The Regence Group serve Idaho, Oregon, Utah and much of Washington state. The Regence Group and each of its affiliate Plans are independent licensees of the Blue Cross and Blue Shield Association.